GFP Adeno-Associated Virus ( AAV-D10 )

Adeno-associated virus (AAV) vectors have become the most important vectors in gene therapy due to their strong transduction efficiency and low pathogenicity. However, one of the pressing challenges is the selective targeting of specific cell types to ensure precise gene delivery. Recent advances have shown that capsid engineering, which involves modifying the protein shell (capsid) that encapsulates the viral genome, provides a promising solution for enhancing AAV vector specificity. Capsid engineering exploits the natural tropism of AAV while introducing modifications that can redirect the vector to the desired cell type. By altering the amino acid sequence on the capsid surface, scientists can create new binding affinities that enhance the ability of the vector to interact with specific cell surface receptors. GFP adeno-associated virus (AAV-D10) is a specialized reporter virus developed through advanced capsid engineering and modification technologies. This modified virus is derived from AAV serotype 2 (AAV2), which is known for its broad host cell targets and relatively low immunogenicity. The strategic insertion of the SRGATTT peptide in the AAV2 capsid is designed to enhance the ability of the virus to target and specifically infect tumor cells. This engineered peptide sequence acts as a tumor homing motif, binding to receptors or molecules that are overexpressed or uniquely present on the surface of tumor cells. As a result, the AAV-D10 virus exhibits a pronounced tropism for cancerous tissues, making it a valuable tool for oncology research and potential therapeutic applications.